Immunotherapy development landscape for bone metastasis - need of predictive preclinical efficacy evaluation for de-risking clinical development

被引：0
|
作者：
Kahkonen, Tiina E.
Halleen, Jussi M.
MacRitchie, Gary
Andersson, Ronnie M.
Bernoulli, Jenni
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2815
引用
收藏
页数：2
相关论文
共 11 条
  • [1] De-Risking Clinical Development
    Greene, Douglas A.
    [J]. GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2012, 32 (03): : 38 - 39
  • [2] De-risking the immunotherapy supply chain: development of virus inactivated human AB serum for immune cell expansion
    Pasley, S.
    Trudel, J.
    Cho, J.
    Zylberberg, C.
    [J]. CYTOTHERAPY, 2020, 22 (05) : S157 - S157
  • [3] De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?
    Arsenault, Benoit J.
    Boekholdt, S. Matthijs
    Tardif, Jean-Claude
    Kastelein, John J. P.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (13) : 1548 - 1550
  • [4] Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective
    Etkin, Amit
    Powell, Jessica
    Savitz, Adam J.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2024,
  • [5] Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
    Joachim Diessner
    Manfred Wischnewsky
    Tanja Stüber
    Roland Stein
    Mathias Krockenberger
    Sebastian Häusler
    Wolfgang Janni
    Rolf Kreienberg
    Maria Blettner
    Lukas Schwentner
    Achim Wöckel
    Catharina Bartmann
    [J]. BMC Cancer, 16
  • [6] Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
    Diessner, Joachim
    Wischnewsky, Manfred
    Stueber, Tanja
    Stein, Roland
    Krockenberger, Mathias
    Haeusler, Sebastian
    Janni, Wolfgang
    Kreienberg, Rolf
    Blettner, Maria
    Schwentner, Lukas
    Woeckel, Achim
    Bartmann, Catharina
    [J]. BMC CANCER, 2016, 16
  • [7] De-Risking Early-Stage Drug Development With a Bespoke Lattice Energy Predictive Model: A Materials Science Informatics Approach to Address Challenges Associated With a Diverse Chemical Space
    Lai, Tiffany
    Pencheva, Klimentina
    Chow, Ernest
    Docherty, Robert
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (10) : 3176 - 3186
  • [8] VALIDATION OF CLINICAL EFFICACY OF LYMPH NODE METASTASIS PREDICTIVE BIOMARKER AND DEVELOPMENT OF RAPID DIAGNOSIS METHOD FOR UTERINE CANCER
    Yoshida, E.
    Terao, Y.
    Ito, Y.
    Ota, T.
    Nojima, M.
    Ogishima, D.
    Kaneda, H.
    Kusunoki, S.
    Fujino, K.
    Hirayama, T.
    Usui, K.
    Itoh, M.
    Kawaji, H.
    Itakura, A.
    Takeda, S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 1216 - 1217
  • [9] Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation
    Picanco-Castro, Virginia
    Bonamino, Martin Hernan
    Ramos, Rodrigo Nalio
    Guerino-Cunha, Renato L.
    Oliveira, Theo Gremen M.
    Rego, Eduardo M.
    [J]. HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2021, 43 : S54 - S63
  • [10] FAVORABLE PRECLINICAL EFFICACY AND SAFETY PROFILE OF AVB-001 A NOVEL IL-2 CELL-BASED IMMUNOTHERAPY THAT ERADICATES OVARIAN CANCER IN MOUSE TUMOR MODELS AND SUPPORTS FIRST IN HUMAN CLINICAL DEVELOPMENT
    Carmona, Guillaume
    Nash, Amanda
    Newman, Ryan
    Schladenhauffen, Jake
    Jarvis, Maria
    Aghlara-Fotovat, Samira
    Mukherjee, Sudip
    Hernandez, Andrea
    Hecht, Andrew
    Rios, Peter
    Nouraein, Shirin
    Sheth, Rahul
    Peng, Weiyi
    Oberholzer, Jose
    Jazaeri, Amir
    Veiseh, Omid
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1137 - A1137
12